Accessibility: Skip TopNav
Lungpacer Announces IDE for STARI Clinical Study
Lungpacer Medical announces Investigational Device Exemption (IDE) for STARI, a Phase 2 Feasibility Clinical Trial.
Format
PNG
Source
Lungpacer Medical USA Inc.
Downloads
Original
Large
Medium
Small